1. New onset severe ulcerative colitis following Ixekizumab therapy.
- Author
-
Morosanu, Alina Mihaela, Mihai, Ioana Ruxandra, Rezus, Ioana Irina, Gavrilescu, Otilia, Dranga, Mihaela, Prelipcean, Cristina Cijevschi, and Mihai, Catalina
- Subjects
- *
ULCERATIVE colitis , *INFLAMMATORY bowel diseases , *THERAPEUTICS , *ANKYLOSING spondylitis , *POISONS , *SHIGELLOSIS - Abstract
Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF